Evidence for the ISG15-specific deubiquitinase usp18 as an antineoplastic target

Lisa Maria Mustachio, Yun Lu, Masanori Kawakami, Jason Roszik, Sarah Joy Spinella, Xi Liu, Ethan Dmitrovsky

Research output: Contribution to journalReview article

Abstract

Ubiquitination and ubiquitin-like posttranslational modifications (PTM) regulate activity and stability of oncoproteins and tumor suppressors. This implicates PTMs as antineoplastic targets. One way to alter PTMs is to inhibit activity of deubiquitinases (DUB) that remove ubiquitin or ubiquitin-like proteins from substrate proteins. Roles of DUBs in carcinogenesis have been intensively studied, yet few inhibitors exist. Prior work provides a basis for the ubiquitin-specific protease 18 (USP18) as an antineoplastic target. USP18 is the major DUB that removes IFN-stimulated gene 15 (ISG15) from conjugated proteins. Prior work discovered that engineered loss of USP18 increases ISGylation and in contrast to its gain decreases cancer growth by destabilizing growth-regulatory proteins. Loss of USP18 reduced cancer cell growth by triggering apoptosis. Genetic loss of USP18 repressed cancer formation in engineered murine lung cancer models. The translational relevance of USP18 was confirmed by finding its expression was deregulated in malignant versus normal tissues. Notably, the recent elucidation of the USP18 crystal structure offers a framework for developing an inhibitor to this DUB. This review summarizes strong evidence for USP18 as a previously unrecognized pharmacologic target in oncology.

Original languageEnglish (US)
Pages (from-to)587-592
Number of pages6
JournalCancer Research
Volume78
Issue number3
DOIs
StatePublished - Feb 1 2018

Fingerprint

Ubiquitin-Specific Proteases
Antineoplastic Agents
Genes
Ubiquitin
Neoplasms
Growth
Ubiquitins
Proteins
Deubiquitinating Enzymes
Ubiquitination
Oncogene Proteins
Post Translational Protein Processing
Lung Neoplasms
Carcinogenesis
Apoptosis

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Mustachio, L. M., Lu, Y., Kawakami, M., Roszik, J., Spinella, S. J., Liu, X., & Dmitrovsky, E. (2018). Evidence for the ISG15-specific deubiquitinase usp18 as an antineoplastic target. Cancer Research, 78(3), 587-592. https://doi.org/10.1158/0008-5472.CAN-17-1752

Evidence for the ISG15-specific deubiquitinase usp18 as an antineoplastic target. / Mustachio, Lisa Maria; Lu, Yun; Kawakami, Masanori; Roszik, Jason; Spinella, Sarah Joy; Liu, Xi; Dmitrovsky, Ethan.

In: Cancer Research, Vol. 78, No. 3, 01.02.2018, p. 587-592.

Research output: Contribution to journalReview article

Mustachio, LM, Lu, Y, Kawakami, M, Roszik, J, Spinella, SJ, Liu, X & Dmitrovsky, E 2018, 'Evidence for the ISG15-specific deubiquitinase usp18 as an antineoplastic target', Cancer Research, vol. 78, no. 3, pp. 587-592. https://doi.org/10.1158/0008-5472.CAN-17-1752
Mustachio, Lisa Maria ; Lu, Yun ; Kawakami, Masanori ; Roszik, Jason ; Spinella, Sarah Joy ; Liu, Xi ; Dmitrovsky, Ethan. / Evidence for the ISG15-specific deubiquitinase usp18 as an antineoplastic target. In: Cancer Research. 2018 ; Vol. 78, No. 3. pp. 587-592.
@article{3d289473b09c40dab0c431acd6ae8894,
title = "Evidence for the ISG15-specific deubiquitinase usp18 as an antineoplastic target",
abstract = "Ubiquitination and ubiquitin-like posttranslational modifications (PTM) regulate activity and stability of oncoproteins and tumor suppressors. This implicates PTMs as antineoplastic targets. One way to alter PTMs is to inhibit activity of deubiquitinases (DUB) that remove ubiquitin or ubiquitin-like proteins from substrate proteins. Roles of DUBs in carcinogenesis have been intensively studied, yet few inhibitors exist. Prior work provides a basis for the ubiquitin-specific protease 18 (USP18) as an antineoplastic target. USP18 is the major DUB that removes IFN-stimulated gene 15 (ISG15) from conjugated proteins. Prior work discovered that engineered loss of USP18 increases ISGylation and in contrast to its gain decreases cancer growth by destabilizing growth-regulatory proteins. Loss of USP18 reduced cancer cell growth by triggering apoptosis. Genetic loss of USP18 repressed cancer formation in engineered murine lung cancer models. The translational relevance of USP18 was confirmed by finding its expression was deregulated in malignant versus normal tissues. Notably, the recent elucidation of the USP18 crystal structure offers a framework for developing an inhibitor to this DUB. This review summarizes strong evidence for USP18 as a previously unrecognized pharmacologic target in oncology.",
author = "Mustachio, {Lisa Maria} and Yun Lu and Masanori Kawakami and Jason Roszik and Spinella, {Sarah Joy} and Xi Liu and Ethan Dmitrovsky",
year = "2018",
month = "2",
day = "1",
doi = "10.1158/0008-5472.CAN-17-1752",
language = "English (US)",
volume = "78",
pages = "587--592",
journal = "Cancer Research",
issn = "0008-5472",
publisher = "American Association for Cancer Research Inc.",
number = "3",

}

TY - JOUR

T1 - Evidence for the ISG15-specific deubiquitinase usp18 as an antineoplastic target

AU - Mustachio, Lisa Maria

AU - Lu, Yun

AU - Kawakami, Masanori

AU - Roszik, Jason

AU - Spinella, Sarah Joy

AU - Liu, Xi

AU - Dmitrovsky, Ethan

PY - 2018/2/1

Y1 - 2018/2/1

N2 - Ubiquitination and ubiquitin-like posttranslational modifications (PTM) regulate activity and stability of oncoproteins and tumor suppressors. This implicates PTMs as antineoplastic targets. One way to alter PTMs is to inhibit activity of deubiquitinases (DUB) that remove ubiquitin or ubiquitin-like proteins from substrate proteins. Roles of DUBs in carcinogenesis have been intensively studied, yet few inhibitors exist. Prior work provides a basis for the ubiquitin-specific protease 18 (USP18) as an antineoplastic target. USP18 is the major DUB that removes IFN-stimulated gene 15 (ISG15) from conjugated proteins. Prior work discovered that engineered loss of USP18 increases ISGylation and in contrast to its gain decreases cancer growth by destabilizing growth-regulatory proteins. Loss of USP18 reduced cancer cell growth by triggering apoptosis. Genetic loss of USP18 repressed cancer formation in engineered murine lung cancer models. The translational relevance of USP18 was confirmed by finding its expression was deregulated in malignant versus normal tissues. Notably, the recent elucidation of the USP18 crystal structure offers a framework for developing an inhibitor to this DUB. This review summarizes strong evidence for USP18 as a previously unrecognized pharmacologic target in oncology.

AB - Ubiquitination and ubiquitin-like posttranslational modifications (PTM) regulate activity and stability of oncoproteins and tumor suppressors. This implicates PTMs as antineoplastic targets. One way to alter PTMs is to inhibit activity of deubiquitinases (DUB) that remove ubiquitin or ubiquitin-like proteins from substrate proteins. Roles of DUBs in carcinogenesis have been intensively studied, yet few inhibitors exist. Prior work provides a basis for the ubiquitin-specific protease 18 (USP18) as an antineoplastic target. USP18 is the major DUB that removes IFN-stimulated gene 15 (ISG15) from conjugated proteins. Prior work discovered that engineered loss of USP18 increases ISGylation and in contrast to its gain decreases cancer growth by destabilizing growth-regulatory proteins. Loss of USP18 reduced cancer cell growth by triggering apoptosis. Genetic loss of USP18 repressed cancer formation in engineered murine lung cancer models. The translational relevance of USP18 was confirmed by finding its expression was deregulated in malignant versus normal tissues. Notably, the recent elucidation of the USP18 crystal structure offers a framework for developing an inhibitor to this DUB. This review summarizes strong evidence for USP18 as a previously unrecognized pharmacologic target in oncology.

UR - http://www.scopus.com/inward/record.url?scp=85041491182&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85041491182&partnerID=8YFLogxK

U2 - 10.1158/0008-5472.CAN-17-1752

DO - 10.1158/0008-5472.CAN-17-1752

M3 - Review article

C2 - 29343520

AN - SCOPUS:85041491182

VL - 78

SP - 587

EP - 592

JO - Cancer Research

JF - Cancer Research

SN - 0008-5472

IS - 3

ER -